-
Bio-Rad Receives FDA Premarket Application Approval for Its Fourth-Generation HIV Assay
Monday, July 25, 2011 - 8:32am | 114Bio-Rad Laboratories, Inc. (NYSE: BIO) and today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's fourth-generation HIV assay, the GS HIV Combo Ag/Ab EIA. The GS HIV Combo Ag/Ab EIA detects HIV antigens (proteins that are part...
-
Response Genetics Announces Search for New CEO
Monday, July 25, 2011 - 8:31am | 102Response Genetics, Inc. (Nasdaq: RGDX) announced today that it intends to hire a new Chief Executive Officer before year end 2011. On July 22, 2011, Kathleen Danenberg stepped down from the position of CEO and was appointed by the Board of Directors to serve as Founder and Executive Scientific and...
-
Response Genetics Announces Search for New CEO
Monday, July 25, 2011 - 8:30am | 102Response Genetics, Inc. (Nasdaq: RGDX) announced today that it intends to hire a new Chief Executive Officer before year end 2011. On July 22, 2011, Kathleen Danenberg stepped down from the position of CEO and was appointed by the Board of Directors to serve as Founder and Executive Scientific and...
-
Accelr8 Announces Continuation and Expansion of BACcel™ Development Collaboration
Monday, July 25, 2011 - 8:04am | 134Accelr8 Technology Corporation (NYSE: AXK) announced that Accelr8 and Novartis have extended their program agreement through September 30, 2011. Having reviewed new data, Novartis will now install a system in their own facility to expand development capacity. While this project proceeds, the...
-
BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
Monday, July 25, 2011 - 7:08am | 52BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the...
-
Thermo Fisher Scientific Earnings Preview: Analyts Expect Higher Earnings, Revenue from Prior Quarter
Friday, July 22, 2011 - 1:11pm | 559Thermo Fisher Scientific (NYSE: TMO) announces its next round of earnings this Wednesday, July 27, 2011. Here's Benzinga's essential guide to Thermo Fisher Scientific's second quarter earnings report. Earnings and Revenue: Analysts are predicting an EPS reading of 98 cents per share and...
-
UPDATE: Jefferies Downgrades Parexel from Buy to UNDERPERFORM and Lowers PT from $29.00 to $19.50
Thursday, July 21, 2011 - 10:32am | 97Jefferies has published a report on Parexel (NASDAQ: PRXL) In the report, Jefferies wrote, "We are downgrading PRXL on concerns of further earnings risk and on valuation that overstates the profitability of new strategic wins. While we believe the wins will translate to significant revenue, the...
-
Jefferies Downgrades ICLR, PRXL
Thursday, July 21, 2011 - 6:32am | 45Jefferies & Company has downgraded the following companies: ICON (NASDAQ: ICLR) from Buy to Hold, PT lowered from $28 to $21.50 PAREXEL (NASDAQ: PRXL) from Buy to Underperform, PT lowered from $29 to $19.50
-
SDIX Launches Apo B Antibody in IVD Market
Wednesday, July 20, 2011 - 4:23pm | 130SDIX (NASDAQ: SDIX) today announced its plan to introduce a new polyclonal antisera to its product line for the IVD market. The product, Apo B, will be available as antisera and in fractionated forms. Antibodies to Apo B will be launched on July 26, 2011, at the annual AACC conference in Atlanta...
-
5 Trade Setups While Waiting For The Market To Do Something
Wednesday, July 20, 2011 - 12:46pm | 225Quiet day in the market so far, and its not tanking (...yet) and is managing to hold on to yesterday's gains (biggest day of the year for the Dow). I've made a number of trades, today, and overall I'm doing fine on the heals of the breakout we got in Hansen Medical (HNSN) today. By the way, for all...
-
Options Brief: Sequenom
Wednesday, July 20, 2011 - 10:22am | 100Shares of Sequenom (NASDAQ: SQNM) are lower on the session by 1.44%, trading at $7.52. Overall call volume is now running at 4.07x the daily average, with 56% of all calls traded being purchases on the offer. 2,715 contracts have traded on the session so far. Sequenom, Inc. is a diagnostic...
-
Options Brief: Illumina
Wednesday, July 20, 2011 - 10:12am | 72Shares of Illumina (NASDAQ: ILMN) are lower on the session by 0.86%, trading at $71.58. Overall call volume is now running at 5.68x the daily average, with 14% of all calls traded being purchases on the offer. 5,956 contracts have traded on the session so far. Illumina, Inc. is a developer and...
-
Genetic Technologies Provides Update Regarding Trading Suspension
Wednesday, July 20, 2011 - 9:10am | 221Genetic Technologies Limited (NASDAQ: GENE) provides the following update to the market regarding its present suspension from trading and proposed capital raising. Before the formal request for a trading halt in the Company's shares (12 July 2011 AEST), Genetic Technologies had been in the process...
-
Jefferies Reports FDA Votes Against BMY Dapagliflozin Approval
Wednesday, July 20, 2011 - 7:47am | 107Jefferies has issued a report that the FDA advisory panel has voted against the approval of Bristol-Myers Squibb's (NYSE: BMY) dapagliflozin. According to the report, "The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (AdCom) voted that the efficacy/ safety data did not provide...
-
AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen Commercial Portfolio and Achieve Cost Synergies
Wednesday, July 20, 2011 - 7:04am | 155AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million. The transaction is...